Abstract: An implant that has a central body or core that functions as a spine, with extending articulating segments that extend from the spine. The articulating segments define a space between each section to allow the implant to be compressed and bent, such that the space between each section can be compressed or expanded. A specific use for the implant is as a sinus implant. Specific embodiments of the implant are useful in correcting missing tissue in the inferior turbinate. Specific embodiments are sized and shaped to treat empty nose syndrome (ENS). Embodiments also relate to an implant that has a port for allowing various fluids or solutions to be flushed into the implant and released through the implant surface.

Abstract: The invention relates generally to systems and devices for material delivery, energy delivery, and/or monitoring electrophysiological activity, and method of use thereof. In particular, the present invention provides devices and systems, and methods of use thereof, configured to deliver therapeutic compositions, to provide electroporation and/or sonoporation to increase therapeutic efficiency, and to monitor electrophysiological activity, for example, before and after treatment.

Abstract: The disclosure provides a medical device and a control method therefor, and a storage medium. The medical device includes a main control circuit, a power module, and functional modules for implementing medical functions of the medical device. The functional modules are powered by the power module and controlled by the main control circuit. The main control circuit is used to determine an idle module in an idle state among the functional modules and set the idle module to be in a low-power state. On the basis of the medical device and the control method therefor and the storage medium according to the embodiments of the disclosure, the overall power consumption of the medical device can be reduced, and the battery life of the medical device is improved.

Abstract: An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.

Abstract: A device includes a capsule sized to pass through a lumen of a gastrointestinal tract; an enteric coating surround at least a portion of the capsule and configured to protect the capsule form stomach acid while allowing degradation of the capsule in the small intestine of the gastrointestinal tract; a plurality of functionalized particles disposed within the capsule, a plurality of tissue penetrating members configured to puncture a wall of the lumen of the intestinal tract; and an actuator having a first configuration and a second configuration. The actuator is configured to retain the plurality of functionalized particles within the capsule in the first configuration. The actuator is further configured to advance the plurality of functionalized particles from the capsule into a wall of the lumen of the gastrointestinal tract via the plurality of tissue penetrating members by the actuator transitioning from the first configuration to the second configuration.

Abstract: The present invention provides an automatic drug delivery device. The automatic drug delivery device includes an enclosure and a first piston disposed in the enclosure. The first piston partitions the enclosure to a first drug delivery chamber and a first expansion chamber. A first through hole and a second through hole are formed in the wall of the enclosure, the first through-hole communicates with the first drug delivery chamber, and the second through-hole communicates with the first expansion chamber. A first targeted dissolution membrane covers the first through hole and the second through hole, and dissolves at a first targeted region. A drug is filled in the first drug delivery chamber, and an expandable material is included in the first expansion chamber. The expandable material in the first expansion chamber can expand after absorbing liquid.

Abstract: This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.

Abstract: The invention relates to a rotor (2, 15) for a fluid pump (1), in particular for use in the medical sphere, the rotor being compressible for bringing to the place of use and thereafter being expandable. The compressibility is assisted by the provision of cavities (27, 28, 29), in particular also production of the rotor at least partially from a foam.

Abstract: The invention relates to a wearable injection device (1) for subcutaneous injection of a therapeutic agent, wherein the dose is injected over a specified period of time after the device is activated.

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

Abstract: An orthopaedic implant includes a support body with a first side having a first inner surface and a second side connected to the first side and having a second inner surface and an outer surface. The first inner surface and the second inner surface each have channels formed within that combine to form a reservoir within the support body. A bone ingrowth layer is attached to the outer surface of the second side.

Abstract: Embodiments are directed to establishing a direct electrical bond between a bonding connector of a contact plate and a battery cell in a battery module. In a first embodiment, an oscillating laser is used to weld the bonding connector to a battery cell terminal over a target area over which the bonding connector makes non-flush contact. In a second embodiment, the bonding connector is flattened to reduce a gap between the bonding connector and the target area on the battery cell terminal, and then laser-welded (e.g., using an oscillating or non-oscillating laser). In a third embodiment, at least one hold-down mechanism is applied over the bonding connector to secure the bonding connector to the battery cell terminal, after which the bonding connector is laser-welded to the battery cell terminal.

Abstract: Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking before and/or after being placed onto the tray. The partially crosslinked hydrogel is frozen and freeze dried. After freeze drying, the hydrogel is conditioned to substantially complete crosslinking, and formed into one or more structures, e.g., plugs, hemostatic, or other medical devices. For example, the hydrogel may be cut, machined, rolled, folded, compressed, and/or cored into that may be loaded into delivery devices that may be introduced into a body to implant or otherwise deliver the structures into the body, e.g., to seal a puncture or other passage through tissue.

Abstract: Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo.

Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane. The rapid swelling of the composition to a size greater than the size of the pyloric sphincter is due to the presence of an osmogen.

Abstract: A controlled release nanoparticulate matter delivery system includes a plurality of thermoresponsive modules containing a respective nanoparticulate matter. Each thermoresponsive module is selectively operable in at least one of a heating mode that releases the nanoparticulate matter and a cooling mode that inhibits release of the nanoparticulate matter. A control module is in electrical communication with the plurality of thermoresponsive modules. The control module is configured to determine a temperature of each thermoresponsive module and to select the at least one heating mode and cooling mode based on the temperature. The heating and cooling mode may be selected in response to a desired dosing profile and/or a biometric condition.

Abstract: Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Abstract: A spacer for a knee replacement prosthesis. The spacer may have a lower surface with a locking component adapted to interlock with a tibial tray, an upper surface optionally with a tibial post and a pair of smooth-surfaced and slightly concave condyle support platforms disposed on opposite sides of the tibial post, and a substantially hollow body with an internal reservoir that can be filled with antibiotic material. The reservoir may be accessible from a port on the hollow body that leads into the internal reservoir, and which permits refilling of the reservoir. In some embodiments, the reservoir may be refillable from this port without removal of the spacer from the patient; for example, a percutaneous needle may be inserted into the port. The spacer may dispense antibiotic from this reservoir to the surrounding area in order to treat an infection.

Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in gastric fluid, wherein the dosage form is weight biased such that one end is heavier than the other end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the fluid with its heavier end pointing generally downwards and into the fluid.

Abstract: The invention relates to a sampling needle, in particular to a needle suitable for oocyte retrieval from a human or animal subject, said needle comprising a first tubular region in fluid communication with a second tubular region, the first tubular region comprising a leading end for insertion into a subject and the second tubular region comprising a trailing end for fluid communication with a means for receiving a fluid, in which the first tubular region has an outer diameter which is less than the outer diameter of the second tubular region and the first tubular region has an inner diameter which is less than the inner diameter of the second tubular region. The invention also relates to a method of retrieving a sample, in particular an oocyte, from a human or animal subject.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: A portal through the sclera for delivery of an effective amount of therapeutic agent to the back of the eye.

Abstract: A controlled release nanoparticulate matter delivery system includes a plurality of thermoresponsive modules containing a respective nanoparticulate matter. Each thermoresponsive module is selectively operable in at least one of a heating mode that releases the nanoparticulate matter and a cooling mode that inhibits release of the nanoparticulate matter. A control module is in electrical communication with the plurality of thermoresponsive modules. The control module is configured to determine a temperature of each thermoresponsive module and to select the at least one heating mode and cooling mode based on the temperature. The heating and cooling mode may be selected in response to a desired dosing profile and/or a biometric condition.

Abstract: A method may include collecting at least one analyte from within a body, ejecting the collected at least one analyte from the body through at least one dermal layer of the body, and receiving the ejected at least one analyte outside the body. A system may include a means for collecting at least one analyte from within a body, a means for ejecting the collected at least one analyte from the body through at least one dermal layer of the body, and a means for receiving the ejected at least one analyte outside the body.

Abstract: A blood clot removal device for removing blood clots from the vascular system of a patient is implantable in the patient's body. The blood clot removal device comprises a blood flow passageway to be connected to the patient's vascular system to allow circulation of the patient's blood through the blood flow passageway, a filter provided in the blood flow passageway for collecting blood clots occurring in the blood flowing through the blood flow passageway, and a cleaning device for moving blood clots collected by the filter out of the blood flow passageway. By means of such blood clot removal device, the risk of blood clots reaching sensitive areas of the patient's body, such as the brain, is reduced.

Abstract: The present invention is generally directed to medical devices, and more specifically to medical devices that are at least partially insertable or implantable into the body of a patient. The medical devices generally comprise (a) a therapeutic agent, more typically, a high-molecular-weight therapeutic agent, and (b) at least one polymeric layer, which typically acts to control the release of the therapeutic agent from the medical device. Also disclosed herein are methods of making such medical devices.

Abstract: An oral dosage form comprising, (i) an erodable core, which core comprises a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof; and (ii) an erodable coating surrounding said core, which coating comprises one or more openings extending substantially completely through said coating but not penetrating said core and communicating from the environment of use to said core; characterized in that release of the pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof from the dosage form occurs through the said opening(s) by the erosion of said erodable core and through erosion of said erodable coating under pre-determined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.

Abstract: Embodiments of a system including a remotely controlled osmotic pump device and associated controller are described. Methods of use and control of the device are also disclosed. According to some embodiments, an osmotic pump device is placed in an environment in order to pump a material into the environment or into an additional fluid handling structure within the osmotic pump device. Exemplary environments include a body of an organism, a body of water, or an enclosed volume of a fluid. In selected embodiments, a magnetic field, an electric field, or electromagnetic control signal may be used.

Abstract: The present invention provides devices, systems, and methods for delivery of an active agent into the eye of a subject. An ocular active agent delivery device can include an active agent reservoir disposed in an annular housing, the annular housing being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule. The device can further allow diffusion of an active agent from the active agent reservoir.

Abstract: Embodiments of a system including a remotely controlled osmotic pump device and associated controller are described. Methods of use and control of the device are also disclosed. According to some embodiments, an osmotic pump device is placed in an environment in order to pump a material into the environment or into an additional fluid handling structure within the osmotic pump device. Exemplary environments include a body of an organism, a body of water, or an enclosed volume of a fluid. In selected embodiments, a magnetic field, an electric field, or electromagnetic control signal may be used.

Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.

Abstract: A portable personal medical device, e.g., a wearable insulin pump, is provided with a web server and is controllable over a network by a browser equipped client, thereby enabling comprehensive and comfortable control, operation and/or configuration of the device.

Abstract: The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing.

Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

Abstract: The filling status of a drug reservoir in a drug pump devices may be determined with mechanical and/or magnetic position sensor associated with a reservoir boundary.

Abstract: A method for evaluating dosing from an implanted infusion system that includes receiving input regarding the identity of a therapeutic agent into an external device. The method further includes displaying on the external device a predetermined set of symptoms associated with the therapeutic agent; receiving input into the external device regarding with which of the symptoms the patient presents; and determining whether the therapeutic agent is being delivered, or has been delivered, at an appropriate dose based on the input identity of the therapeutic agent and the input symptoms.

Abstract: A number of parameters related to the operation of a fluid delivery device are determined based on a pressure within the device sensed using a pressure sensor. In one example, the volume of therapeutic fluid added to or removed from a reservoir of a fluid delivery device is determined based on a sensed pressure of the reservoir. In another example, the volume of therapeutic fluid added to or removed from the reservoir is determined based on a sensed pressure of a refill port assembly of the device. In another example, an initial temperature of the reservoir as a therapeutic fluid is removed from the reservoir is estimated based on a sensed pressure within the device. In another example, a temperature of a therapeutic fluid added to the reservoir is estimated based on a sensed pressure within the device.

Abstract: An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir.

Abstract: An expiration time of a therapeutic fluid delivered by an implantable fluid delivery device is employed to calculate a fill volume and determine a refill interval for the fluid. The expiration time of the therapeutic fluid may be based on or dictated by a stability time set by the manufacturer of the therapeutic fluid, a clinician treating a patient to whom the fluid is to be delivered, the manufacturer of the device delivering the fluid, or combinations thereof.

Abstract: A system and method are provided for securing an ingestible electronic device to a pharmaceutical product without damaging the ingestible electronic device. The product includes the ingestible electronic device being placed on the product in accordance with one aspect of the present invention. In accordance with another aspect of the present invention, the ingestible electronic device is placed inside the product. Various embodiments are disclosed in accordance with the present invention for protecting and/or coating of the electronic marker as well as securing the ingestible electronic device onto the product.

Abstract: Embodiments of the invention disclose a system for controlled oral drug delivery. The system comprising a removable device comprising a drug to be delivered, wherein the drug is delivered based on osmotic pressure generated in the removable device. Further, the system comprises a receptacle to hold the removable device in an oral cavity, and a base station configured to dock the removable device for determining information about one or more characteristics of the removable device.

Abstract: Methods for setting a basal rate profile for an insulin pump, wherein the basal rate profile defines a basal rate delivery for a selected time interval and has a pre-defined number of profile segments each of which define the basal rate delivery for a subset of the selected time interval, include providing a curve representing the basal rate as a continuous function of time as an input for an input unit and generating the basal rate profile from the curve by a calculation unit by assigning curve values at selected time instances to the pre-defined number of profile segments.

Abstract: An osmotic pump includes a plurality of agent reservoirs; first and second solute chambers; a semi-permeable membrane separating the first and second solute chambers from one another; a flexible membrane separating a first one of the agent reservoirs from the first solute chamber; and a plurality of valves. Each of the valves is moveable between an open position in which a corresponding one of the agent reservoirs is open to an outlet of the pump and a closed position in which the corresponding one of the agent reservoirs is sealed with respect to the pump outlet.

Abstract: A device includes a first reservoir configured to include a degradation agent, a second reservoir configured to include an osteogenerative agent, and a controller configured to selectively initiate access to the first reservoir or the second reservoir.

Abstract: A device includes a sensor configured to determine a condition associated with a nucleus pulposus, a reservoir configured to include a first agent capable of affecting the condition associated with the nucleus pulposus, a control element configured to provide access to the reservoir, and a controller in communication with the sensor and the control element. The controller is configured to manipulate the control element to provide access to the reservoir in response to the condition determined by the sensor.

Abstract: Devices, systems and methods for delivering pre-determined quantities of an active ingredient to a biological system are provided. In various embodiments, a device for controlled release of an active ingredient is provided, including a release aperture operably associated with a deflectable member, a base with a porous membrane substrate layer, and at least one chamber juxtaposed between the release aperture and the porous membrane layer. The chamber may contain a matrix including one or more active ingredients and an agent that expands when contacted with an aqueous solution. The device is suitable for implantation in a biological system and can be used for delayed and/or time release of specific drug dosages for various indications.

Abstract: An environmentally sensitive hydrogel material swells or collapses in response to a parameter such as pH level associated with consumption of food by a patient. This swelling or collapsing is harnessed to treat morbid obesity or some other condition of the patient. The swelling or collapsing of the hydrogel may be used to tighten a gastric band or gastric valve when the patient starts eating; then loosen the band or valve when the patient is between meals. The swelling or collapsing of the hydrogel may also be used to increase the size of a space occupying device in the patient's stomach when the patient starts eating; then decrease the size of the space occupying device when the patient is between meals. The swelling or collapsing of the hydrogel may also be used to selectively restrict the absorption of nutrients within a patient's gastrointestinal tract, such as in the duodenum.

Abstract: The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing.

Abstract: Embodiments of an implantable electrolytic pump include a first expandable diaphragm and a second flexible diaphragm, and first and second chambers each for containing a fluid, wherein the first expandable diaphragm separates the first and second chambers and provides a fluid barrier therebetween, and the second chamber is formed between the first expandable diaphragm and the second flexible diaphragms. The pump may further include electrolysis electrodes within the first chamber for causing generation of a gas therein and to thereby expand the expandable diaphragm so that fluid is forced from the second chamber into a cannula.

Abstract: An orifice device for delivering one or more drugs includes an inner member having a proximal end and a distal end; and a winding helically wound around the inner member. The winding includes a plurality of distinct wires helically wound in parallel around the inner member. The winding and the inner member define at least three separate channels for carrying one or more drugs therethrough. An inlet is at the proximal end of the winding and an outlet is at the distal end of the winding for the plurality of distinct wires. In some embodiments, at least two of the plurality of distinct wires have a different dimension. An outer member is used over the winding. Also, at least two of the at least three separate channels have a different fluid flow rate. And, in some embodiments, at least two of the at least three separate channels carry a different drug.